 EVALUATING THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A PRIME-BOOST REGIMEN OF HIV-1 NEFTATVIF, ENV PDNA VACCINE DELIVERED INTRAMUSCULARLY WITH ELECTROPORATION AND HIV-1 RVSV ENVC VACCINE IN HEALTHY, HIV-UNINFECTED ADULTS: 